Phase Ib/IIa trial of TapImmune's TPIV-100 vaccine in patients with HER2/neu-positive breast cancer

Trial Profile

Phase Ib/IIa trial of TapImmune's TPIV-100 vaccine in patients with HER2/neu-positive breast cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs TPIV 100 (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2018 According to a TapImmune media release, this study is fully funded by a grant from the U.S. DoD.
    • 15 Nov 2017 According to a TapImmune media release, this trial is expected to begin in 1H 2018.
    • 07 Jun 2016 According to a TapImmune media release, the company plans to initiate this trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top